Wei Li – Global Chief Investment Strategist, Kurt Reiman – Senior Strategist for North America, and Michel Dilmanian – Investment Strategist all forming part of the BlackRock Investment Institute, share their insights on global economy, markets and geopolitics. Their views are theirs alone and are not intended to be construed as investment advice.
Key Points
Value vs, growth: We think value stocks can outperform as interest rates head higher. Regions and sectors help us find quality within value and growth at a reasonable price.
Market backdrop: Stocks slid after the Federal Reserve’s preferred inflation gauge showed persistently high inflation, reinforcing why we see more rate hikes ahead.
Week ahead: We see a tight labor market in the euro area keeping core inflation elevated. China’s services PMI should show the economy’s rapid restart is playing out.
Growth stocks have led the U.S. equity rally so far this year, halting outperformance in 2022 by value equities. We believe value stocks can resume their climb as major central banks keep interest rates higher for longer. Higher rates reduce the value of future cash flows, weighing more on growth stocks and reinforcing our developed market equities underweight. Underneath that, our sector and region preferences tilt to value with quality attributes and growth at a reasonable price.
Value vs. Growth
The new regime is not a typical business cycle and requires a new playbook. That applies to equity style factors, too, in our view. Value stocks – or those seen as undervalued relative to fundamentals – lagged growth stocks for much of the past decade (left chart). That switched abruptly in 2022 when central banks started rapidly tightening policy – only to be followed by a value dip early this year on hopes for policy easing (right chart). We think value can regain the lead. Why? Higher interest rates and inflation, and a steeper yield curve. That all favors value over growth, in our view. It’s not about choosing one factor over another: Factors mean different things to different people, and the composition of factors also changes over time. Case in point: The healthcare sector is now a modest overweight in the MSCI USA Value index compared with an underweight in 2008.
Our macro view supports a case for value over growth. Higher interest rates feed into higher discount rates, making future cash flows of growth stocks less attractive. We also think persistent inflation is likely to lead investors to demand more compensation for holding long-term government bonds, driving yields higher. Value tends to outperform when the yield curve steepens, we find. While value historically underperforms heading into recession because capital-intensive companies can’t respond quickly to changing cycles, we think that could be different in this atypical economic cycle. Value is still attractive after being beaten down for so long. Companies in the value bucket have also had time to prepare for a well-telegraphed downturn. Case in point: Many banks have already provisioned for losses in advance of a recession. Lastly, we expect a mild recession, so we think the performance impact is likely to be softer on value companies than in past cycles.
Getting Granular
Our current asset allocations across regions and sectors have a value tilt with quality characteristics. We find that emerging markets (EM) and Europe have a consistent value bias when looking at the composition of indexes and key company metrics. For sectors, we see energy as a fusion of value and quality. We find value in the sector after being unloved and undisciplined with capital in the past. We think its stronger balance sheets, better investor payouts and improved return on equity give it more of a quality tilt. We find value in financials as well, but not the same quality. We see the sector capitalizing on higher rates with improved net interest margins after years of ultra-low or negative rates in some cases.
Healthcare has become more of a value sector but also has characteristics of growth. This speaks again to how factors can have different meanings and evolve over time. We like healthcare for its growth prospects but at the right price – valuations look reasonable to us relative to other growth sectors. We also see quality in healthcare’s defensive characteristics during a recession and think aging populations bolster structural growth in demand.
Bottom line
We prefer to be selective within our cautious view of developed market equities. We like sectors and regions with a value bent while we stay nimble in this new regime of heightened macro and market volatility. We think structurally higher inflation, higher-for-longer interest rates and our expectation for a steeper yield curve all favor value. We find value in the energy and financial sectors and focus on quality within these sectors. We also like healthcare but at a reasonable price.
Market backdrop
Global stocks retreated further this week, with European equities faring better than U.S. peers. Short-term U.S. yields jumped to a 16-year high, with the yield curve at its most inverted since the early 1980s. The U.S. PCE inflation data showed stubbornly high core inflation. This reinforces our view that sticky inflation likely means major central banks will have to hike rates further and keep them higher for longer to bring it back down to their 2% targets.
Euro area inflation data this week will be key for gauging how much higher the European Central Bank might lift policy rates. We’re also watching unemployment data for signs of further labor market tightness that could stoke persistently high core inflation. China’s services PMI will help assess how rapid the economy’s restart has been.
Week Ahead
Feb. 28: U.S. consumer confidence
Mar 1: U.S. ISM manufacturing PMI
Mar 2: Euro area unemployment and flash inflation
Mar 3: China Caixin services PMI
Euro area inflation data this week will be key for gauging how much higher the European Central Bank might lift policy rates. We’re also watching unemployment data for signs of further labor market tightness that could stoke persistently high core inflation. China’s services PMI will help assess how rapid the economy’s restart has been.
BlackRock’s Key risks & Disclaimers:
This material is not intended to be relied upon as a forecast, research or investment advice, and is not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. The opinions expressed are as of 21st February, 2023 and may change. The information and opinions are derived from proprietary and non-proprietary sources deemed by BlackRock to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by BlackRock, its officers, employees or agents. This material may contain ’forward looking’ information that is not purely historical in nature. Such information may include, among other things, projections and forecasts. There is no guarantee that any forecasts made will come to pass. Reliance upon information in this material is at the sole discretion of the reader.
The information provided here is neither tax nor legal advice. Investors should speak to their tax professional for specific information regarding their tax situation. Investment involves risk including possible loss of principal. International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation, and the possibility of substantial volatility due to adverse political, economic or other developments. These risks are often heightened for investments in emerging/developing markets or smaller capital markets.
Issued by BlackRock Investment Management (UK) Limited, authorized and regulated by the Financial Conduct Authority. Registered office: 12 Throgmorton Avenue, London, EC2N 2DL.
MeDirect Disclaimers:
This information has been accurately reproduced, as received from BlackRock Investment Management (UK) Limited. No information has been omitted which would render the reproduced information inaccurate or misleading. This information is being distributed by MeDirect Bank (Malta) plc to its customers. The information contained in this document is for general information purposes only and is not intended to provide legal or other professional advice nor does it commit MeDirect Bank (Malta) plc to any obligation whatsoever. The information available in this document is not intended to be a suggestion, recommendation or solicitation to buy, hold or sell, any securities and is not guaranteed as to accuracy or completeness.
The financial instruments discussed in the document may not be suitable for all investors and investors must make their own informed decisions and seek their own advice regarding the appropriateness of investing in financial instruments or implementing strategies discussed herein.
If you invest in this product you may lose some or all of the money you invest. The value of your investment may go down as well as up. A commission or sales fee may be charged at the time of the initial purchase for an investment. Any income you get from this investment may go down as well as up. This product may be affected by changes in currency exchange rate movements thereby affecting your investment return therefrom. The performance figures quoted refer to the past and past performance is not a guarantee of future performance or a reliable guide to future performance. Any decision to invest in a mutual fund should always be based upon the details contained in the Prospectus and Key Information Document (KID), which may be obtained from MeDirect Bank (Malta) plc.
